Latest advanced heart failure Stories
SAN DIEGO, May 29, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases announced today it had been selected as a winner of Red Herring's Top 100 North America award, a prestigious list honoring the year's most promising private technology ventures from the North American business region. "We are proud to have been selected as a winner of this award and we are thankful to...
First heart pacemaker able to recruit stem cells to damaged heart tissue - THE MYOSTIM PACER - will be introduced LOS ANGELES, May 1, 2013 /PRNewswire/ -- Heart Rhythm 2013 will be held in Denver, Colorado May 8th to 11th - http://www.hrsonline.org/. Leonhardt Ventures and MyoStim Pacers are co-sponsoring @ 3pm on May 9(th) at their exhibit booth No. 657 a showcase of technologies that address heart and cardiovascular disease. Companies to be showcased include: MyoStim Pacers -...
SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first European patient in its ongoing international Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). The Phase 2b study titled "Calcium Up-Regulation by Percutaneous Administration of...
PLEASANTON, Calif., Dec. 11, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that the company has received approval from Japan's Ministry of Health, Labour and Welfare to market HeartMate II®( )as a Bridge-to-Transplantation therapy for patients suffering from advanced heart failure. "Approval in Japan marks a significant milestone in...
FRAMINGHAM, Mass. and SYDNEY, Nov. 20, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare(®) Ventricular Assist System as a bridge to heart transplantation in patients with...
SAN DIEGO, Aug. 29, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first patient in a Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). Chronic HF is a leading cause of hospitalization and resulted in direct and indirect costs of $39.2 billion to the U.S....
FRAMINGHAM, Mass. and SYDNEY, May 23, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the publication of results from ADVANCE, the Company's U.S. clinical trial evaluating the use of the HeartWare® Ventricular Assist System as a bridge to heart transplantation in patients with advanced...
FRAMINGHAM, Mass. and SYDNEY, May 8, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that enrollment is complete in ENDURANCE, the Company's pivotal Destination Therapy clinical study to evaluate the use of the HeartWare® Ventricular Assist System in patients with end-stage heart failure....
Lowering glucose levels for people with diabetes is normally critical to improving health outcomes. But for those with heart failure, that might not always be the case, say UCLA researchers. A new study found that for advanced heart failure patients with diabetes, having higher blood glucose levels may actually help improve survival rates. Currently published online in the American Journal of Cardiology, UCLA researchers compared levels of a marker used to track glucose levels called...
First patient successfully receives donor heart. Second patient on Freedom Driver. NORFOLK, Va., March 6, 2012 /PRNewswire-USNewswire/ -- Living without a heart. What was once only a far off concept has now become a reality for advanced heart failure patients in need of more time to await a heart transplant. (Photo: http://photos.prnewswire.com/prnh/20120306/DC65557) Physicians at Sentara Heart Hospital have begun offering the Total Artificial Heart (TAH) as the latest...
